拆方益肝康的两种药物血清对HSC活化增殖的影响  

Seropharmacological effects of Yigankang and its separated recipe on activation and proliferation of hepatic stellate cells

作　　者：房红梅[1] 姚希贤[1] 姚金峰[1] 王军民[1] 

机构地区：[1]河北医科大学第二医院消化内科,河北省石家庄市050000

出　　处：《世界华人消化杂志》2005年第16期1970-1973,共4页World Chinese Journal of Digestology

基　　金：河北省中医管理局资助项目;No.200335~~

摘　　要：目的:探讨中药复方益肝康抗肝纤维化的作用机制及药效学配伍意义.方法:分别给正常大鼠及CCl4造模肝纤维化大鼠灌服益肝康及其拆方—丹参小复方(丹参、黄芪、归尾),提取药物血清,温育体外培养的肝星状细胞.3H-TdR掺入法测定细胞增殖,免疫细胞化学法检测α-SMA表达.结果:两种方法制备的益肝康及丹参小复方药物血清对HSC的3H-TdR掺入及α-SMA表达均有抑制作用.A组(正常大鼠药物血清)中,益肝康及丹参小复方药物血清50mL/L浓度组对3H-TdR掺入抑制作用与对照组相比无显著性差异(P>0.05),而100、200mL/L浓度组均具有显著性差异(拆方:14.48%,25.95%vs0,全方:16.66%,23.77%vs0,P<0.01);全方与拆方各浓度组对α-SMA表达的抑制作用与对照组相比均有显著性差异(吸光度:0.042±0.002,0.048±0.001vs0.061±0.004,P<0.01).B组(肝纤维化大鼠药物血清)中:50、100、200mL/L益肝康及丹参小复方药物血清组对3H-TdR掺入(全方:8.02%,18.36%,29.53%vs0,拆方:7.44%,16.80%,30.01%vs0,均/9<0.01).及α-SMA表达抑制作用与对照组相比均具有显著性差异(吸光度:0.038±0.001,0.044±O.002vs0.065±0.002,均P<0.01).相应浓度的全方与拆方药物血清之间对3H-TdR掺入抑制率无显著性差异(P>0.05),对α-SMA表达的抑制作用全方优于拆方(P<0.05).肝纤维化大鼠药物血清对3H-TdR掺入及α-SMA表达抑制作用优于正常大鼠药物血清(P<0.05).结论:益肝康及丹参小复方可抑制肝星状细胞活化增殖,全方作用优于拆方,肝纤维化大鼠药物血清作用优于正常大鼠药物血清.AIM： To investigate the seropharmacological effects of Yigankangand its separated recipe （SR） on the activation and proliferation of hepatic stellate cells （HSCs）, and to explore the antifibrotic mechanism of Yigankang. METHODS： Normal rats and rats with CCl4-induced liver fibrosis were given Yigankang and its separated recipe （containing radix salviae militiorrhizae, astragalus and angelica sinensis） to prepare the medicated serums. After incubation with the serums, the proliferation of HSCs was measured by H3-TdR incorporation, and the expression of α-smooth muscle actin （α-SMA） was detected by immunocytochemistry. RESULTS： Both kinds of medicated serums from normal rats and rats with liver fibrosis had inhibitory effects on 3H- TdR incorporation and α-SMA expression. In group A （medicated serum from normal rats）, 50 ml/L medicated serum had no significant inhibition on the proliferation of HSCs as compared with the control serum （P〉0.05）, while 100 and 200 ml/L ones had （SR： 14.48%, 25.95% vs 0, Yigankang. 16.66%, 23.77% vs 0, P〈0.01 ）. The expres sion of α-SMA was markedly lower in SR and Yigankang group than that in the control group （opticaldensity： 0.048 ± 0.001,0.042 ± 0.002 vs 0.061 ± 0.004,both P〈0.01）. In group B （medicated serum from rats withliver fibrosis）, the serum at the concentrations of 50, 100and 200 mL/L inhibited the proliferation of HSCs signifi-cantly （SR： 7.44%, 16.80%, 30.01% vs O, Yigankang：8.02%, 18.36%, 29.53% vsO, P〈0.01）. The level of α-SMAexpression was obviously lower in SR and Yigankanggroup than that in the control group （optical density：0.044 ± 0.002, 0.038 ± 0.001 vs 0.065 ± 0.002, bothP〈0.01 ）. SR and Yigankang at the same concentrationhad the same inhibition on 3H-TdR incorporation （P〉0.05）,but for the expression of α-SMA, Yigankang had a stron-ger inhibitory effect （P〈0.05）. The inhibitions of 3H-TdRincorporation and α-SMA expression were more evidentin group B than those in group

关 键 词：益肝康 肝纤维化 肝星状细胞 Α-平滑肌肌动蛋白 药物血清 活化增殖 ^3H-TdR掺入法 HSC 拆方 Α-SMA表达 

分 类 号：R285.5[医药卫生—中药学] R392.12[医药卫生—中医学]